Y mAbs Therapeutics

Yahoo Finance • 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNT, DAY, WOW, YMAB on Behalf of Shareholders

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verint Systems Inc. (Nasdaq – VRNT), Dayforce, Inc. (NYSE – DAY), WideOpenWest, Inc. (NYSE – WOW), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)

BALA CYNWYD, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DAY, WOW, YMAB, STAA on Behalf of Shareholders

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Dayforce, Inc. (NYSE- DAY), WideOpenWest, Inc. (NYSE - WOW), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)

BALA CYNWYD, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VBTX, TASK, YMAB on Behalf of Shareholders

NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutic... Full story

Yahoo Finance • 2 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger of DNOW, TASK, SQCF, and YMAB

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story

Yahoo Finance • 2 months ago

Y-mAbs Therapeutics’ SWOT analysis: acquisition shakes up oncology stock outlook

Y-mAbs Therapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-based cancer therapies, has recently become the subject of significant market attention. The company, known for its FDA-approved drug Danyelza... Full story

Yahoo Finance • 2 months ago

The trading volume of these stocks is deviating from the norm in today's session.

Volume analysis on 2025-08-08: stocks with an unusual volume in today's session. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 46.49% Today's trading... Full story

Yahoo Finance • 2 months ago

Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates

Investing.com - Y mAbs Therapeutics (NASDAQ: YMAB) reported second quarter EPS of $-0.07, $0.19 better than the analyst estimate of $-0.26. Revenue for the quarter came in at $19.53M versus the consensus estimate of $18.37M. Y mAbs Ther... Full story

Yahoo Finance • 2 months ago

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; tra... Full story

Yahoo Finance • 2 months ago

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based ther... Full story

Yahoo Finance • 2 months ago

Unusual volume stocks are being observed in Wednesday's session.

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT TNON [https://www.chartmill.com/stock/quote/TNON/profile] 7.14% The... Full story

Yahoo Finance • 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, BASE, CORZ on Behalf of Shareholders

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)

BALA CYNWYD, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 3 months ago

Leptomeningeal Metastases Market Research Report 2025-2035 | Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics

Company Logo Leptomeningeal metastases (LM), the spread of cancer to the brain's and spinal cord's protective tissues, pose severe challenges, stemming from cancers like breast and lung. Rising cancer survival rates have increased LM inci... Full story

Yahoo Finance • 3 months ago

Y-mAbs Therapeutics announces results of annual shareholder meeting votes

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a biotechnology company with a market capitalization of $192 million and a strong financial health rating according to InvestingPro, held its annual meeting of stockholders on Friday, July 11, where... Full story

Yahoo Finance • 4 months ago

Y-mAbs Therapeutics' SWOT analysis: oncology biotech stock faces growth hurdles

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a market capitalization of $213.34 million, is navigating a complex landscape in the oncology therapeutics market. The company, known for its focus... Full story

Yahoo Finance • 5 months ago

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugat... Full story

Yahoo Finance • 5 months ago

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunothe... Full story